CNS Pharmaceuticals, Inc. (BE50)
XFRA 
NASDAQ (CM) Primary XFRA Summary
BE50 Chart
CNS Pharmaceuticals, Inc. (CNSP) Shareholder/Analyst Call Prepared Remarks Transcript
CNS Pharmaceuticals, Inc. ( CNSP ) Shareholder/Analyst Call November 17, 2025 12:00 PM EST Company Participants John Climaco - CEO, President & Director Christopher Downs - Chief Financial Officer Presentation John Climaco CEO, President & Director Welcome, everyone. The Annual Meeting of the Stockholders of CNS Pharmaceuticals, Inc. is hereby convened and called to order.
Why Is CNS Pharmaceuticals (CNSP) Stock Down 69% Today?
CNS Pharmaceuticals (NASDAQ: CNSP ) stock is heading lower on Tuesday after the clinical-pharmaceutical company announced an expansion to its pipeline. CNS Pharmaceuticals has acquired an exclusive license and the intellectual property rights to TPI 287.
CNS Pharmaceuticals, Inc. (BE50) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has CNS Pharmaceuticals, Inc. ever had a stock split?
CNS Pharmaceuticals, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Rami Levin CEO | XFRA Exchange | US18978H5081 ISIN |
| US Country | 4 Employees | - Last Dividend | 22 Jul 2025 Last Split | 8 Nov 2019 IPO Date |
Overview
CNS Pharmaceuticals, Inc. is a distinguished clinical pharmaceutical company dedicated to the innovation of anti-cancer drug candidates, focusing on the treatment of brain and central nervous system tumors. Established in 2017, the company has rapidly positioned itself as a significant player in the medical research field, working towards pioneering solutions for one of the most challenging aspects of oncology. CNS Pharmaceuticals holds its headquarters in Houston, Texas, reflecting its strategic location within a hub of scientific and medical research excellence. Through strategic collaborations with leading institutions and companies, including Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center, CNS Pharmaceuticals aims to fast-track the development and commercialization of its innovative drug candidates. Moreover, a pivotal development agreement with WPD Pharmaceuticals Inc. underscores its commitment to expanding its research and development capabilities on a global scale.
Products and Services
-
Berubicin:
The company's flagship drug candidate, Berubicin, represents a groundbreaking approach in the battle against glioblastoma multiforme, a notoriously aggressive type of brain tumor. Having successfully completed a Phase I clinical trial, Berubicin exemplifies the potential for novel chemotherapy agents to penetrate the blood-brain barrier effectively. This capability marks a significant stride towards addressing one of the most formidable challenges in treating central nervous system tumors. The development and continual refinement of Berubicin underline CNS Pharmaceuticals' dedication to improving patient outcomes in glioblastoma multiforme therapy.
